BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li N, Deng W, Zhang G, Du Y, Guo Y, Ma Y, Wei C, Bie L, Zhang C, Song T, Luo S, Fang B. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. Front Oncol 2021;11:728854. [PMID: 34540697 DOI: 10.3389/fonc.2021.728854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Huang H, Zhang T, Feng H, Wang S, Zhang Y, Ji X, Cheng X, Zhao R. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. Front Immunol 2022;13:937307. [DOI: 10.3389/fimmu.2022.937307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chen Y, Xu YY, Jiang HJ, Wang L, Zhai JW, Zhang T, Yang YF. Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction. Chin J Integr Med 2022. [PMID: 35508862 DOI: 10.1007/s11655-022-3676-7] [Reference Citation Analysis]